No Approved Use in Infants
Lurbinectedin (brand name Zepzelca) is approved by the FDA for adults with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy.[1] It has no approval or recommended use in infants or children, as clinical trials and labeling exclude pediatric populations due to lack of data and potential risks from its mechanism as an alkylating-like agent targeting DNA repair.[2]
Standard Adult Administration
Adults receive lurbinectedin as a 30-minute intravenous (IV) infusion of 3.2 mg/m² every 21 days, typically with supportive care like antiemetics and growth factor prophylaxis for neutropenia.[1][3] Dosing adjustments occur for toxicity, but no infant-specific guidelines exist.
Why Not for Infants?
Infants lack the organ maturity (e.g., liver, kidneys) to safely metabolize lurbinectedin, which undergoes CYP3A4 hepatic clearance and risks severe myelosuppression, hepatotoxicity, and rhabdomyolysis.[1][4] Pediatric oncology protocols favor age-appropriate chemotherapies; off-label extrapolation from adult doses is not standard and could be fatal due to higher relative toxicity in small bodies.[5]
Pediatric Oncology Alternatives
For infant cancers like neuroblastoma or embryonal tumors, treatments use infant-tailored regimens (e.g., low-dose cyclophosphamide, topotecan via IV over 30 minutes daily x5 days).[6] Consult NCCN pediatric guidelines or a specialist for any rare compassionate use scenarios.
[1]: FDA Zepzelca Label
[2]: Drugs.com - Lurbinectedin
[3]: Zepzelca HCP Site
[4]: PubMed - Lurbinectedin Pharmacokinetics
[5]: COG Pediatric Protocols
[6]: NCCN Pediatric Guidelines